Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    More than 95% of people who take treatment are cured of hepatitis C. In other words, they no longer have the virus.Modern hepatitis C treatment...

    From: The basics

    Information level Level 1
  • Medications for hepatitis C

    DAAs target different steps of HCV reproduction. These include HCV protease inhibitors, polymerase inhibitors and NS5A inhibitors. Recommended regimens include at least two drugs that work in different...

    From: Booklets

    Information level Level 2
  • Treatment for people with HIV and HCV co-infection

    In the UK, standards for HIV treatment and care are set and monitored by the British HIV Association (BHIVA), the professional association for HIV doctors and other healthcare...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment

    Effective direct-acting antiviral or 'DAA' medicines, used without interferon, can now cure most people with hepatitis C. This includes people who previously were considered to be more difficult...

    From: Booklets

    Information level Level 2
  • Hepatitis C and HIV

    Hepatitis C is a blood-borne infection that is transmitted in some of the same ways as HIV.Over time untreated hepatitis C...

    From: Factsheets

    Information level Level 2

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Cash Incentives, Peer Support May Not Incentivize HCV Treatment

    A randomized trial comparing a cash incentive to peer support for increasing acceptance of treatment for hepatitis C virus (HCV) among persons with HCV/HIV coinfection, including those who use drugs or alcohol, found both methods helpful but that 1 in 4 patients still declined treatment.

    10 May 2019 | MD Magazine
  • England hits WHO 2020 hepatitis C target three years early

    Deaths from liver disease related to serious hepatitis C (HCV) fell by more than 16% between 2015 and 2017, according to data published by Public Health England (PHE). As a result, England has hit the World Health Organization’s (WHO’s) target to reduce HCV related mortality by 10% by 2020 three years early.

    18 April 2019 | The Pharmaceutical Journal
  • Summary from CROI 2019 for viral Hepatitis, from Jürgen Rockstroh

    Although no new drugs for HBV or HCV therapy were presented a whole range of important clinical studies were discussed which all have important clinical implications for daily practice.

    09 April 2019 | NATAP
  • Hepatitis C deaths fall by 16 per cent between 2015 and 2017

    Deaths from serious hepatitis C related liver disease fell by 16.1% between 2015 and 2017 according to data from PHE.

    09 April 2019 | Public Health England
  • Armenia gets license to produce drugs for hepatitis C treatment

    The Armenian Ministry of Health and the Gilead Science Ireland UC have signed a Memorandum of Understanding, under which Gilead will provide Armenia with a license to produce, pack and import genetic drugs for hepatitis C treatment.

    03 April 2019 | Public Radio of Armenia
  • San Francisco Study Shows Engagement in HCV Care Aids Elimination

    In San Francisco, many transwomen have access to hepatitis C virus (HCV) testing and treatment, which suggests an opportunity for HCV control and elimination, according to a study recently published in the Journal of Viral Hepatitis.

    02 April 2019 | Infectious Disease Advisor
  • Louisiana picks drug company for hepatitis C treatment plan

    Gilead Sciences subsidiary Asegua Therapeutics LLC won the contract, selected from three companies that sought to partner with the state. Louisiana will pay a fee to the drug manufacturer for unlimited access to its hepatitis C medication, a generic version of Epclusa, for five years.

    27 March 2019 | San Francisco Chronicle
  • Pilot study finds HCV treatment safe in pregnancy

    A small pilot study of hepatitis C treatment in pregnant women found that that the treatment was effective in achieving hepatitis C cure and identified no safety concerns associated with treatment, according to findings presented at CROI.

    11 March 2019 | Healio
  • 'Patient No. 1' from a Hep C heart transplant study shares his story

    By the time three transplant physicians approached Tom Giangiulio Jr. about being the first patient in a new clinical trial to accept a heart from a Hepatitis C-positive donor, Giangiulio didn’t have much of a choice.

    08 March 2019 | Cardiovascular Business
  • Hepatitis C Treatment Market to Exceed US$ 71.13 Bn by the end of 2024

    The global hepatitis C treatment market was valued at US$ 23.9 Bn in 2015 and is estimated to be valued at US$ 26.6 Bn by 2016. The market is expected to reach a valuation of US$ 71.13 Bn by the end of 2024, reflecting a cumulative annual growth rate of 13.1% over the forecast period.

    04 March 2019 | Honest Businessman
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.